# Biotech Daily Digest â€” 2025-09-17

**45 items from 6 sources**

## Summary by Source

- Eli Lilly Press Releases: 2 items
- Endpoints News: 12 items
- Fierce Biotech: 9 items
- MHRA â€“ News: 1 item
- Regeneron Press Releases: 2 items
- arXiv q-bio: 19 items


## Eli Lilly Press Releases

- **[Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head)**  
  _Wed, 17 Sep 2025 09:00:00 -0400_  
  For the primary endpoint,Â orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs. 11.0 lbs (5.3%) with oral semaglutide, a 73.6% relative improvement, in a key secondary endpoint

- **[Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight)**  
  _Tue, 16 Sep 2025 18:01:00 -0400_  
  The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study Â Orforglipron demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions


## Endpoints News

- **[#EADV25: Leo Pharma details mid-stage win for IL-22 targeting antibody in atopic dermatitis](https://endpoints.news/eadv25-leo-pharma-details-mid-stage-win-for-il-22-targeting-antibody-in-atopic-dermatitis/)**  
  _Wed, 17 Sep 2025 14:00:38 +0000_  
  Months after Leo Pharma said its drug candidate for atopic dermatitis delivered positive results in a Phase 2b trial, the company finally revealed details of its success.

 The highest three doses of the companyâ€™s temtokibart ...

- **[Joe Jimenez's new biotech inks up to $1B biobuck deal for Mabwell's cardio siRNA](https://endpoints.news/joe-jimenezs-new-biotech-inks-up-to-1b-biobuck-deal-for-mabwells-cardio-sirna/)**  
  _Wed, 17 Sep 2025 13:32:58 +0000_  
  Aditum Bio, a biotech investment firm that also runs clinical development for its portfolio companies, has done another licensing deal in China.

 The firm, which was founded by former Novartis CEO Joe Jimenez, created a ...

- **[Lilly's diabetes pill beats Novo's Rybelsus in head-to-head trial, company mulls fast-track filing](https://endpoints.news/lillys-diabetes-pill-beats-novos-in-head-to-head-trial-company-mulls-fast-track-filing/)**  
  _Wed, 17 Sep 2025 13:00:43 +0000_  
  Eli Lilly said Wednesday that orforglipron beat Novo Nordiskâ€™s oral drug Rybelsus in a head-to-head trial in diabetes patients, the latest twist in the Indianapolis drugmaker's efforts to get its obesity pill to market.  ...

- **[Affini-T CEO appears to have left startup, raising questions about company's shutdown](https://endpoints.news/affini-t-ceo-appears-to-have-left-startup-raising-questions-about-companys-shutdown/)**  
  _Wed, 17 Sep 2025 12:18:28 +0000_  
  Affini-T Therapeutics, a biotech seeking to make cell therapies into solid tumor killers, appears to have lost its last senior executive, raising the likely possibility that the company is winding down â€” or already has.  ...

- **[AstraZeneca's Fasenra once again falls short in COPD](https://endpoints.news/astrazenecas-fasenra-once-again-falls-short-in-copd/)**  
  _Wed, 17 Sep 2025 11:09:23 +0000_  
  AstraZenecaâ€™s attempt to expand Fasenraâ€™s label in chronic obstructive pulmonary disease has failed one more time after the company reported the drug did not succeed in another Phase 3 trial.

 The drugmaker

- **[Roivant tees up dermatomyositis drug filing on heels of Phase 3 success](https://endpoints.news/roivant-tees-up-dermatomyositis-drug-filing-on-heels-of-phase-3-success/)**  
  _Wed, 17 Sep 2025 11:00:40 +0000_  
  Roivant said a candidate it licensed from Pfizer for an autoimmune disease has passed a registrational test in dermatomyositis, sparking plans for an NDA filing next year.

 The dual inhibitor of TYK2 and JAK1, called ...

- **[Ollin lands $100M to test eye drugs from Chinese partners and bring in more assets](https://endpoints.news/ollin-lands-100m-to-test-eye-drugs-from-chinese-partners-and-bring-in-more-assets/)**  
  _Wed, 17 Sep 2025 10:30:15 +0000_  
  Another US biotech has emerged with rights to experimental medicines that were created by China-based drug developers.

 On Wednesday, Austin, TX-based Ollin Biosciences debuted with $100 million in funding to create new ophthalmology treatments from ...

- **[#EADV25: Sanofi claims Phase 2a success in chronic skin condition](https://endpoints.news/eadv25-sanofi-claims-phase-2a-success-in-chronic-skin-condition/)**  
  _Wed, 17 Sep 2025 05:00:02 +0000_  
  One of Sanofiâ€™s newer immunological drugs has succeeded in a Phase 2a study for a chronic skin condition, the company announced Wednesday.

 In a study looking at 71 patients with hidradenitis suppurativa, Sanofi said 67 ...

- **[#EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo's oral Wegovy](https://endpoints.news/easd25-lilly-unwraps-more-phase-3-obesity-pill-data-but-results-continue-to-lag-novos-oral-wegovy/)**  
  _Tue, 16 Sep 2025 22:01:48 +0000_  
  VIENNA â€” Additional results from a late-stage trial studying Eli Lilly's closely-watched GLP-1 pill orforglipron further underscore its lackluster performance when lined up against the oral form of Novo Nordiskâ€™s Wegovy.

 In the Phase 3 ATTAIN ...

- **[Drugmakers submit plans to join 340B rebate model pilot program](https://endpoints.news/drugmakers-submit-plans-to-join-340b-rebate-model-pilot-program/)**  
  _Tue, 16 Sep 2025 19:52:48 +0000_  
  All eligible drugmakers have applied to participate in the governmentâ€™s pilot program testing a rebate model for certain 340B drug discounts, an HHS spokesperson said.

 Novartis and Bristol Myers Squibb confirmed to Endpoints News  ...

- **[Pfizer, Novartis, BMS, Lilly and others targeted in FDA's TV ad crackdown](https://endpoints.news/pfizer-novartis-bms-lilly-and-others-targeted-in-fdas-tv-ad-crackdown/)**  
  _Tue, 16 Sep 2025 19:27:05 +0000_  
  The FDA on Tuesday released 40 letters sent to companies as part of its crackdown on pharmaceutical ads, revealing some of its criticisms on how risks and benefits of drugs are presented.

 The

- **[Ark, Atom file to go public in Hong Kong; Aptevoâ€™s stock rallies on AML data](https://endpoints.news/ark-atom-file-to-go-public-in-hong-kong-aptevos-stock-rallies-on-aml-data/)**  
  _Tue, 16 Sep 2025 14:58:22 +0000_  
  Plus, news about Apollo Therapeutics, Reunion Neuroscience, Basilea, Tafalgie Therapeutics, Areteia Therapeutics and Avidity Biosciences:

 ðŸ‡¨ðŸ‡³ Two more biotechs look to IPO in Hong Kong: Ark Biopharmaceutical in Shanghai and  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/jjs-il-23-drug-defeats-reigning-champ-sotyktu-phase-3-psoriasis-trial" hreflang="en">J&amp;J's IL-23 drug defeats reigning champ Sotyktu in phase 3 psoriasis trial</a>](https://www.fiercebiotech.com/biotech/jjs-il-23-drug-defeats-reigning-champ-sotyktu-phase-3-psoriasis-trial)**  
  _Sep 17, 2025 9:24am_  
  After being touted as a potential rival to Bristol Myers Squibbâ€™s reigning oral psoriasis med Sotyktu for months, Johnson & Johnsonâ€™s IL-23 drug looks like it has a real shot at taking the crown.

- **[<a href="https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-ultra-rare-disease-bouncing-back-spark-race-fda" hreflang="en">Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA</a>](https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-ultra-rare-disease-bouncing-back-spark-race-fda)**  
  _Sep 17, 2025 9:01am_  
  Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. The biotech plans to file for FDA approval of garetosmab in fibrodysplasia ossificans progressiva by the end of 2025 on the strength of a pivotal trial that read out on Wednesday.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-rounds-out-oral-glp-1-weight-loss-data-posts-semaglutide-topping-results-diabetes-it" hreflang="en">Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes</a>](https://www.fiercebiotech.com/biotech/lilly-rounds-out-oral-glp-1-weight-loss-data-posts-semaglutide-topping-results-diabetes-it)**  
  _Sep 17, 2025 8:02am_  
  At this yearâ€™s meeting of the European Association for the Study of Diabetes in Vienna, Eli Lilly bolstered the case for its oral GLP-1 orforglipron, showing that its pill can both stand on its own in obesity and go toe-to-toe with a rival candidate from Novo Nordisk in diabetes.

- **[<a href="https://www.fiercebiotech.com/biotech/roivant-reports-phase-3-autoimmune-win-ex-pfizer-asset" hreflang="en">Roivant reports phase 3 autoimmune win for ex-Pfizer asset</a>](https://www.fiercebiotech.com/biotech/roivant-reports-phase-3-autoimmune-win-ex-pfizer-asset)**  
  _Sep 17, 2025 6:21am_  
  A phase 3 trial of Priovant Therapeuticsâ€™ inflammatory disease prospect brepocitinib has hit its primary endpoint, setting the Roivant-backed biotech up to seek FDA approval for the TYK2/JAK1 inhibitor next year.

- **[<a href="https://www.fiercebiotech.com/biotech/eye-disease-biotech-launches-100m-and-sights-set-roche-showdown" hreflang="en">Eye disease biotech launches with $100M and sights set on Roche showdown</a>](https://www.fiercebiotech.com/biotech/eye-disease-biotech-launches-100m-and-sights-set-roche-showdown)**  
  _Sep 16, 2025 1:20pm_  
  During his tenure at Genentech, ophthalmologist Jason Ehrlich supported the development of Rocheâ€™s blockbuster eye disease med Vabysmo. Now, as the co-founder and CEO of newly launched Ollin Biosciences, Ehrlich seeks to topple the titan he helped create with the aid of $100 million and an antibody sourced from China.

- **[<a href="https://www.fiercebiotech.com/medtech/thermo-fisher-debuts-multiplex-protein-panel-neurodegenerative-disease-research" hreflang="en">Thermo Fisher debuts multiplex protein panel for neurodegenerative disease research</a>](https://www.fiercebiotech.com/medtech/thermo-fisher-debuts-multiplex-protein-panel-neurodegenerative-disease-research)**  
  _Sep 16, 2025 11:20am_  
  The addition of the multiplex immunoassay panel to the companyâ€™s Target 48 proteomics line follows last yearâ€™s $3.1 billion acquisition of Olink.

- **[<a href="https://www.fiercebiotech.com/biotech/genmab-discards-clinical-adc-picked-last-years-18b-profoundbio-buy" hreflang="en">Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy</a>](https://www.fiercebiotech.com/biotech/genmab-discards-clinical-adc-picked-last-years-18b-profoundbio-buy)**  
  _Sep 16, 2025 10:34am_  
  Genmab has dropped an antibody-drug conjugate picked up as part of its $1.8 billion ProfoundBio buyout, citing an inadequate benefit-risk profile.

- **[<a href="https://www.fiercebiotech.com/biotech/apollos-15m-bet-il-18-antibody-pays-phase-2-eczema-win" hreflang="en">Apollo's $15M bet on IL-18 antibody pays off with phase 2 eczema win</a>](https://www.fiercebiotech.com/biotech/apollos-15m-bet-il-18-antibody-pays-phase-2-eczema-win)**  
  _Sep 16, 2025 8:47am_  
  Apollo Therapeuticsâ€™ $15 million bet on Avaloâ€™s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis.

- **[<a href="https://www.fiercebiotech.com/biotech/catalym-taps-4-industry-vets-lets-go-3-leaders-c-suite-change" hreflang="en">CatalYm taps 4 industry vets, lets go of 3 leaders in C-suite change-up</a>](https://www.fiercebiotech.com/biotech/catalym-taps-4-industry-vets-lets-go-3-leaders-c-suite-change)**  
  _Sep 15, 2025 10:53am_  
  CatalYm has tapped four industry leaders to take up spots at the immunotherapy biotech, a move that has prompted three other executives to hit the exit.


## MHRA â€“ News

- **[Guidance: International Recognition Procedure](https://www.gov.uk/government/publications/international-recognition-procedure)**  
  _2025-09-17T07:44:38Z_  
  How to use the procedure for medicines licensing applications.


## Regeneron Press Releases

- **[Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD](https://investor.regeneron.com/news-releases/news-release-details/results-phase-2-courage-trial-demonstrating-potential-improve)**  
  _Wed, 17 Sep 2025 09:30:00 -0400_  
  Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss Numeric improvements in metabolic and lipid parameters including waist

- **[Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-phase-3-trial-adults-ultra-rare)**  
  _Wed, 17 Sep 2025 07:00:00 -0400_  
  FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both number and volume of abnormal bone lesions (heterotopic ossification, or HO lesions)


## arXiv q-bio

- **[Behavioral-feedback SIR epidemic model: analysis and control](https://arxiv.org/abs/2509.12257)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12257v1 Announce Type: new 
Abstract: This paper investigates a behavioral-feedback SIR model in which the infection rate adapts dynamically based on the fractions of susceptible and infected individuals. We introduce an invariant of motion and we characterize the peak of infection. We further examine the sâ€¦

- **[Genome-Factory: An Integrated Library for Tuning, Deploying, and Interpreting Genomic Models](https://arxiv.org/abs/2509.12266)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12266v1 Announce Type: new 
Abstract: We introduce Genome-Factory, an integrated Python library for tuning, deploying, and interpreting genomic models. Our core contribution is to simplify and unify the workflow for genomic model development: data collection, model tuning, inference, benchmarking, and interâ€¦

- **[RNA-binding antiterminators: regulation of metabolism and pathogenicity in bacteria](https://arxiv.org/abs/2509.12293)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12293v1 Announce Type: new 
Abstract: Antiterminators are essential components of bacterial transcriptional regulation, allowing the control of gene expression in response to fluctuating environmental conditions. Among them, RNA-binding antiterminator proteins play a major role in preventing transcription tâ€¦

- **[MHASS: Microbiome HiFi Amplicon Sequencing Simulator](https://arxiv.org/abs/2509.12428)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12428v1 Announce Type: new 
Abstract: Summary: Microbiome HiFi Amplicon Sequence Simulator (MHASS) creates realistic synthetic PacBio HiFi amplicon sequencing datasets for microbiome studies, by integrating genome-aware abundance modeling, realistic dual-barcoding strategies, and empirically derived pass-nuâ€¦

- **[Computational design of intrinsically disordered proteins](https://arxiv.org/abs/2509.12460)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12460v1 Announce Type: new 
Abstract: Protein design has the potential to revolutionize biotechnology and medicine. While most efforts have focused on proteins with well-defined structures, increased recognition of the functional significance of intrinsically disordered regions, together with improvements iâ€¦

- **[The Inhibition of B16-F10 Mouse Melanoma Cell Proliferation in Increased Concentration Levels of Theophylline](https://arxiv.org/abs/2509.12655)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12655v1 Announce Type: new 
Abstract: Cancer is a complex sequence of disease conditions progressing gradually with generalized loss of growth control. It continues to be one of the biggest global health problems, and its etiology has given rise to a huge array of treatment outside of conventional chemotherâ€¦

- **[Emergent complexity and rhythms in evoked and spontaneous dynamics of human whole-brain models after tuning through analysis tools](https://arxiv.org/abs/2509.12873)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12873v1 Announce Type: new 
Abstract: The simulation of whole-brain dynamics should reproduce realistic spontaneous and evoked neural activity across different scales, including emergent rhythms, spatio-temporal activation patterns, and macroscale complexity. Once a mathematical model is selected, its confiâ€¦

- **[Synthetic Protein-Ligand Complex Generation for Deep Molecular Docking](https://arxiv.org/abs/2509.12915)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12915v1 Announce Type: new 
Abstract: The scarcity of experimental protein-ligand complexes poses a significant challenge for training robust deep learning models for molecular docking. Given the prohibitive cost and time constraints associated with experimental structure determination, scalable generationâ€¦

- **[ORCA: A Comprehensive AI-Driven Platform for Digital Pathology Analysis and Biomarker Discovery](https://arxiv.org/abs/2509.13044)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13044v1 Announce Type: new 
Abstract: Digital pathology has emerged as a transformative approach to tissue analysis, offering unprecedented opportunities for objective, quantitative assessment of histopathological features. However, the complexity of implementing artificial intelligence (AI) solutions in paâ€¦

- **[Flow-Based Fragment Identification via Binding Site-Specific Latent Representations](https://arxiv.org/abs/2509.13216)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13216v1 Announce Type: new 
Abstract: Fragment-based drug design is a promising strategy leveraging the binding of small chemical moieties that can efficiently guide drug discovery. The initial step of fragment identification remains challenging, as fragments often bind weakly and non-specifically. We develâ€¦

- **[Uchimata: a toolkit for visualization of 3D genome structures on the web and in computational notebooks](https://arxiv.org/abs/2509.13290)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13290v1 Announce Type: new 
Abstract: Summary: Uchimata is a toolkit for visualization of 3D structures of genomes. It consists of two packages: a Javascript library facilitating the rendering of 3D models of genomes, and a Python widget for visualization in Jupyter Notebooks. Main features include an expreâ€¦

- **[Accelerating Protein Molecular Dynamics Simulation with DeepJump](https://arxiv.org/abs/2509.13294)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13294v1 Announce Type: new 
Abstract: Unraveling the dynamical motions of biomolecules is essential for bridging their structure and function, yet it remains a major computational challenge. Molecular dynamics (MD) simulation provides a detailed depiction of biomolecular motion, but its high-resolution tempâ€¦

- **[An Assembly-Line Mechanism for In-Vitro Encapsulation of Fragmented Cargo in Virus-Like Particles](https://arxiv.org/abs/2509.12409)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12409v1 Announce Type: cross 
Abstract: The ability of virus shells to encapsulate a wide range of functional cargoes, especially multiple cargoes - siRNAs, enzymes, and chromophores - has made them an essential tool in biotechnology for advancing drug delivery applications and developing innovative new matâ€¦

- **[A Multimodal Foundation Model to Enhance Generalizability and Data Efficiency for Pan-cancer Prognosis Prediction](https://arxiv.org/abs/2509.12600)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12600v1 Announce Type: cross 
Abstract: Multimodal data provides heterogeneous information for a holistic understanding of the tumor microenvironment. However, existing AI models often struggle to harness the rich information within multimodal data and extract poorly generalizable representations. Here we pâ€¦

- **[Spatiotemporal graph neural process for reconstruction, extrapolation, and classification of cardiac trajectories](https://arxiv.org/abs/2509.12953)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12953v1 Announce Type: cross 
Abstract: We present a probabilistic framework for modeling structured spatiotemporal dynamics from sparse observations, focusing on cardiac motion. Our approach integrates neural ordinary differential equations (NODEs), graph neural networks (GNNs), and neural processes into aâ€¦

- **[SHREC 2025: Protein surface shape retrieval including electrostatic potential](https://arxiv.org/abs/2509.12976)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12976v1 Announce Type: cross 
Abstract: This SHREC 2025 track dedicated to protein surface shape retrieval involved 9 participating teams. We evaluated the performance in retrieval of 15 proposed methods on a large dataset of 11,555 protein surfaces with calculated electrostatic potential (a key molecular sâ€¦

- **[Bioluminescence in turbulence: intermittent straining lights up dinoflagellates](https://arxiv.org/abs/2509.13273)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13273v1 Announce Type: cross 
Abstract: Dinoflagellates are marine phytoplankton that emit flashes of light in response to flow-induced deformation; they are responsible for illuminating breaking-waves, wakes of ships, and other intensely turbulent spots of the upper ocean. Here, we ask how bioluminescenceâ€¦

- **[Overcoming classic challenges for artificial neural networks by providing incentives and practice](https://arxiv.org/abs/2410.10596)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2410.10596v4 Announce Type: replace-cross 
Abstract: Since the earliest proposals for artificial neural network (ANN) models of the mind and brain, critics have pointed out key weaknesses in these models compared to human cognitive abilities. Here we review recent work that uses metalearning to overcome severalâ€¦

- **[Controlling tissue size by active fracture](https://arxiv.org/abs/2503.03126)**  
  _Wed, 17 Sep 2025 00:00:00 -0400_  
  arXiv:2503.03126v2 Announce Type: replace-cross 
Abstract: Groups of cells, including clusters of cancerous cells, multicellular organisms, and developing organs, may both grow and break apart. What physical factors control these fractures? In these processes, what sets the eventual size of clusters? We first developâ€¦
